Biotechnology · Miami Beach, Florida, United States
$3.92
+3.70% (+$0.14)2026-07-09
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$18.9M
EPS$-0.35
Market Cap$296.9M
Price Performance
Historical data including institutional events
Company Profile
S
Samuel Reich
CEO & Executive Director
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
The company was founded in 2014 and is headquartered in Miami Beach, Florida.
